ENFLONSIA™
(clesrovimab-cfor) 105 mg injection

Billing and Coding Guide for ENFLONSIA

Billing Codes

This resource contains lists of codes that may be relevant for ENFLONSIA and its administration. This information is current as of August 1, 2025. The information provided here is not intended to be conclusive or exhaustive. You are solely responsible for determining the appropriate codes and for any action you take in billing. The use of this information does not guarantee payment or that any payment received will cover your costs.

Every reasonable effort has been made to verify the accuracy of the information; however, this reference is not intended to provide specific guidance on how to utilize, code, bill, or charge for any product or service. Merck does not make any warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for any particular use. The use of this information does not guarantee payment or that any payment received will cover your costs.

Indications and Usage

ENFLONSIA is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

Select Safety Information

- Do not administer ENFLONSIA to infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONSIA.
- Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
- ENFLONSIA may interfere with some immunologically-based RSV diagnostic assays (i.e., rapid antigen tests) as observed in laboratory studies. Confirmation using a reverse transcriptase polymerase chain reaction (RT-PCR) assay is recommended when rapid antigen assay results are negative and clinical observations are consistent with RSV infection.
- The most common adverse reactions were injection-site erythema (3.8%), injection-site swelling (2.7%), and rash (2.3%).

Billing Codes

ENFLONSIA™ (clesrovimab-cfor) 105 mg injection

Immune Globulin and Administration Codes[1,2]

Because ENFLONSIA is a monoclonal antibody, a passive immunization for RSV and not a vaccine, ENFLONSIA has been assigned a CPT code within the immune globulins, serum, or recombinant products section of the CPT code book. This code should be assigned to all claims for ENFLONSIA.

CPT Code for ENFLONSIA	
90382	Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use[1]

Because ENFLONSIA has an immune globulin product code, administration codes specific to the administration of a RSV monoclonal antibody should be assigned to claims.

Administration CPT Codes	Descriptor
96380	Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional[2]
96381	Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection[2]

CPT, Current Procedural Terminology. CPT is a registered trademark of the American Medical Association.

Diagnosis Code[3]

ICD-10-CM Code	Descriptor
Z29.11	Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV)[3]

ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification.

Select Safety Information

- Do not administer ENFLONSIA to infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONSIA.
- Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
- ENFLONSIA may interfere with some immunologically-based RSV diagnostic assays (i.e., rapid antigen tests) as observed in laboratory studies. Confirmation using a reverse transcriptase polymerase chain reaction (RT-PCR) assay is recommended when rapid antigen assay results are negative and clinical observations are consistent with RSV infection.
- The most common adverse reactions were injection-site erythema (3.8%), injection-site swelling (2.7%), and rash (2.3%).

Billing Codes (*continued*)

ENFLONSIA™ (clesrovimab-cfor) 105 mg injection

Additional Coding and Packaging Information

Entity: Merck Sharp & Dohme LLC

Product	NDC	Package	CVX/ MVX Codes[4]	Catalog Price
ENFLONSIA 105 mg injection	10-Digit: 0006-5073-01 11-Digit: 00006-5073-01	Package containing 1 single-dose 0.7-mL prefilled syringe	332/MSD	$556.00
ENFLONSIA 105 mg injection	10-Digit: 0006-5073-02 11-Digit: 00006-5073-02	Package containing 10 single-dose 0.7-mL prefilled syringes	332/MSD	$5,560.00

Please note: The NDC above is the billable NDC that appears on the carton.

NDC, National Drug Code; CVX, Clinical Vaccines Administered; MVX, Manufacturers of Vaccines.

Billing for Visits and Immunization[5]

If an immunization is the only service provided, a visit should not be billed. If an immunization is provided during a visit with other services, it may be appropriate to bill separately for the visit if it is significant and separately identifiable, in which case the visit code may be reported with modifier 25. It is best practice to consult payer-specific requirements.

VFC Billing[6]

When billing for public sector immunizations supplied through the VFC Program, it is recommended to consult each state's Medicaid provider manuals and billing guidance because billing policies can differ between states. Some states require the submission of the CPT code for the product, while others require the submission of the appropriate immunization administration code to receive an administration fee.

VFC, Vaccines for Children.

Select Safety Information

- Do not administer ENFLONSIA to infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONSIA.
- Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
- ENFLONSIA may interfere with some immunologically-based RSV diagnostic assays (i.e., rapid antigen tests) as observed in laboratory studies. Confirmation using a reverse transcriptase polymerase chain reaction (RT-PCR) assay is recommended when rapid antigen assay results are negative and clinical observations are consistent with RSV infection.
- The most common adverse reactions were injection-site erythema (3.8%), injection-site swelling (2.7%), and rash (2.3%).

Before administering ENFLONSIA, please read the accompanying Prescribing Information.
The Patient Information also is available.

References

1. American Medical Association (AMA). CPT Category I New Immunization Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors. Updated July 1, 2025. Accessed July 21, 2025. https://www.ama-assn.org/system/files/vaccine-long-descriptors.pdf
2. American Medical Association. CPT 2025 Professional Edition. 1st ed. American Medical Association; 2024:868–870.
3. ICD-10-CM tabular list of diseases and injuries. Centers for Medicare & Medicaid Services. Last updated February 26, 2025. Accessed April 8, 2025. https://www.cms.gov/medicare/coding-billing/icd-10-codes
4. Centers for Disease Control and Prevention (CDC). Immunization Information Systems (IIS). IIS: HL7 Standard Code Set Mapping product names to CVX and MVX. Last reviewed July 21, 2025. Accessed August 1, 2025. https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=tradename
5. Centers for Medicare & Medicaid Services. NCCI Policy Manual for Medicare: Chapter XI medicine evaluation and management services CPT codes 90000-99999 for national correct coding initiative policy manual. Revised January 1, 2024. Accessed June 9, 2025. https://www.cms.gov/files/document/medicare-ncci-policy-manual-2024-chapter-11.pdf
6. Frequently asked questions for the pediatric immunization administration codes. American Academy of Pediatrics. Published November 2024. Accessed March 31, 2025. https://downloads.aap.org/AAP/PDF/coding_faq_immunization_administration.pdf

MERCK

Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

US-RSM-00146 11/25